S.A. Mason LLC Decreases Stake in Illumina, Inc. (NASDAQ:ILMN)

S.A. Mason LLC lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,770 shares of the life sciences company’s stock after selling 150 shares during the quarter. S.A. Mason LLC’s holdings in Illumina were worth $246,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Brown Brothers Harriman & Co. grew its stake in Illumina by 460.9% in the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock valued at $45,000 after purchasing an additional 106 shares during the period. State of Wyoming bought a new position in Illumina during the second quarter valued at about $32,000. Penserra Capital Management LLC bought a new position in Illumina during the first quarter valued at about $64,000. ST Germain D J Co. Inc. purchased a new stake in Illumina during the second quarter worth about $36,000. Finally, Annis Gardner Whiting Capital Advisors LLC bought a new stake in Illumina in the third quarter worth about $30,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $138.68 on Thursday. The business has a 50-day moving average price of $138.29 and a two-hundred day moving average price of $129.31. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $233.42. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. Illumina’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS. Research analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday, February 14th. StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. HSBC cut Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Sanford C. Bernstein raised Illumina from an “underperform” rating to a “market perform” rating in a report on Friday, December 15th. Finally, Wolfe Research began coverage on shares of Illumina in a report on Wednesday, December 13th. They set an “outperform” rating and a $175.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $166.95.

Insiders Place Their Bets

In related news, CEO Jacob Thaysen acquired 7,330 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was purchased at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the purchase, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.13% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.